Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study.

MedStar author(s):
Citation: 2019/04/30/Department: MedStar Georgetown University Hospital ResidentsForm of publication: Poster PresentationYear: 2019Conference information: MedStar Health-Georgetown University Research Symposium, North Bethesda, MD., All authors: Khoury K, Isaacs C, Gatti-Mays M, Donahue R, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain S, Pohlmann P, Lynce F. Fiscal year: FY2019Local accession number: C2019_353Date added to catalog: 2021-01-11
Holdings
Item type Current library Collection Call number Status Date due Barcode
Poster Presentation MedStar Authors Catalog Poster Available

Powered by Koha